infect
result
evalu
encourag
none
use
herbal
prepar
contract
sar
health
worker
infect
improv
influenzalik
symptom
qualiti
life
qol
measur
also
observ
less
report
minor
advers
event
observ
allow
conclus
deduct
sinc
trial
neither
random
placebocontrol
chaotic
period
deadli
epidem
measur
ensur
proper
conduct
trial
simpli
lack
nevertheless
studi
immunolog
state
herbal
consum
indic
object
evid
improv
bodi
defens
system
two
week
treatment
interestingli
booster
effect
subsid
two
week
later
therefor
consid
explor
efficaci
herbal
prepar
justifi
plan
proper
random
control
trial
thu
construct
sinc
annual
record
depart
health
hong
kong
indic
endem
influenza
like
appear
februari
april
everi
year
prevent
program
could
organ
within
period
accordingli
primari
object
studi
investig
efficaci
herbal
prepar
previous
use
prevent
sar
endem
influenza
among
group
risk
elderli
peopl
unpredictabley
annual
endem
happen
primari
object
would
chang
control
influenza
like
syndrom
secondari
object
includ
safeti
use
prepar
chang
qol
among
user
studi
design
doubleblind
placebocontrol
random
trial
target
particip
dweller
oldag
home
attend
elderli
centr
age
total
elderli
centr
old
age
home
randomli
select
new
territori
hong
kong
inclus
criteria
includ
enjoy
stabl
health
influenzalik
symptom
enrol
written
inform
consent
obtain
particip
entri
studi
studi
protocol
approv
properli
clinic
research
ethic
committe
princ
wale
hospit
exclus
criteria
includ
histori
hypersensit
herb
regular
consum
herbal
prepar
medic
known
upset
immunomodul
function
eg
steroid
sever
cognit
dysfunct
receiv
influenza
vaccin
past
six
month
would
ask
join
blood
sampl
group
elig
particip
alloc
randomli
doubleblind
way
one
two
treatment
group
accord
comput
gener
stratif
random
block
design
stratif
made
oldag
homeelderli
centr
vaccin
statu
oldag
home
elderli
centr
particip
random
separ
within
vaccin
group
nonvaccin
group
receiv
either
herbal
prepar
placebo
particip
receiv
g
sachet
herbal
prepar
placebo
altern
day
week
week
particip
stop
take
either
herbal
prepar
placebo
follow
research
interview
end
anoth
week
placebo
made
starch
colour
resembl
herbal
tea
studi
period
particip
instruct
keep
daili
record
bodi
temperatur
symptom
sore
throat
myalgia
run
nose
cough
resembl
symptom
influenza
research
interview
telephon
particip
twice
week
gather
updat
data
individu
particip
requir
report
interview
time
suspect
contract
influenzalik
ill
bodi
temperatur
nasopharyng
swab
would
taken
individu
research
nurs
sent
viral
investig
influenzalik
symptom
advers
reaction
observ
qol
evalu
week
subgroup
recruit
examin
blood
immunolog
marker
total
particip
receiv
influenza
vaccin
within
month
studi
recruit
consent
voluntari
basi
requir
give
ml
blood
week
administr
either
herbal
placebo
intervent
everi
herbal
compon
test
heavi
metal
microbi
pesticid
contamin
test
result
met
safeti
requir
hong
kong
formula
prepar
granul
readi
consumpt
drink
qualifi
laboratori
licens
good
manufactur
practic
hong
kong
chines
medicin
industri
develop
centr
hong
kong
institut
vocat
educ
hong
kong
china
formula
contain
commonli
use
herb
moru
alba
l
chrysanthemum
morifolium
ramat
prunu
armeniaca
l
forsythia
suspens
vahl
mentha
haplocalyx
briq
platycodon
grandi
florum
jacq
dc
glycyrrhiza
glabra
l
phragmit
communi
trin
scutellaria
baicalensi
georgi
isati
indigotica
fort
astragalu
membranaceu
fisch
bge
saposhnikovia
divaricata
turcz
schischk
placebo
manufactur
laboratori
prepar
match
herbal
drink
satisfactorili
colour
tast
primari
outcom
number
episod
influenza
influenzalik
ill
detect
two
differ
group
incid
influenzalik
ill
defin
fever
plu
presenc
least
one
influenza
symptom
eg
sore
throat
cough
run
nose
myalgia
case
fever
nasopharyng
swab
collect
laboratori
detect
influenza
pathogen
qol
evalu
use
questionnair
vital
mental
health
subscal
immunolog
state
read
blood
sampl
immunolog
paramet
includ
b
lymphocyt
lymphocyt
thelper
lymphocyt
tsuppressor
lymphocyt
natur
killer
nk
cell
basic
hematolog
complet
blood
count
white
blood
cell
biochemistri
renal
liver
function
includ
safeti
studi
data
manag
use
spss
softwar
particip
demograph
first
present
descript
overal
subgroup
aspect
parametr
nonparametr
statist
analysi
method
use
test
chang
health
statu
flulik
syndrom
immunolog
statu
safeti
profil
take
studi
drink
intentiontotreat
analysi
appli
dec
juli
total
subject
screen
elderli
home
elderli
centr
subject
met
inclus
subject
agre
join
studi
respons
rate
among
subject
subject
agre
provid
blood
sampl
immunolog
assess
random
particip
randomli
alloc
either
herbal
placebo
group
recruit
written
consent
sign
sixtysix
particip
drop
shortli
commenc
anoth
particip
drop
follow
visit
total
particip
declin
particip
respect
belong
herbal
placebo
group
reason
withdraw
relat
person
prefer
mild
advers
event
list
flow
chart
figur
baselin
signific
differ
herbal
placebo
group
materi
includ
age
gender
habit
herbdietari
supplement
intak
medic
condit
shown
tabl
also
renal
liver
function
particip
volunt
provid
blood
sampl
immunolog
assess
within
normal
rang
studi
period
first
time
five
year
record
depart
health
hong
kong
outbreak
influenza
endem
either
gener
famili
clinic
depart
health
privat
sector
protocol
design
meet
endem
therefor
studi
modifi
target
control
influenzalik
syndrom
particip
report
us
fever
symptom
resembl
influenza
howev
nasopharyng
swab
show
neg
result
viral
cultur
statist
differ
fever
occurr
herbal
placebo
group
vs
tabl
symptom
run
nose
less
herbal
group
placebo
group
tabl
qol
mental
health
vital
health
improv
herbal
placebo
group
treatment
period
washout
period
p
tabl
signific
differ
two
group
note
student
ttest
use
continu
variabl
test
fisher
exact
test
use
categor
variabl
twotail
fever
last
week
treatment
start
miss
case
vaccin
case
vaccin
nonvaccin
group
compar
symptom
improv
symptom
herbal
drink
signific
differ
found
two
group
particip
herbal
group
placebo
group
report
mild
advers
effect
dizzi
headach
sputum
diarrhea
common
mild
advers
effect
thirtyon
particip
withdrew
herbal
placebo
group
respect
due
mild
advers
event
mild
advers
event
subsid
day
either
dropout
group
studi
group
probabl
report
symptom
directli
relat
herbal
prepar
tabl
antivir
formula
creat
combin
two
popular
classic
formula
sangju
decoct
yupingfeng
powder
modifi
supplement
two
herbal
item
known
antivir
trial
design
accord
annual
expect
influenza
endem
happen
consecut
year
uncertain
reason
particip
volunt
blood
check
treatment
particip
lost
followup
due
person
reason
thu
subject
provid
baselin
poststudi
blood
sampl
immunolog
state
differ
group
baselin
nk
absolut
count
significantli
enhanc
herbal
group
p
tabl
immunolog
paramet
signific
differ
major
subject
receiv
influenza
vaccin
within
month
studi
expect
endem
occur
trial
instead
clinic
trial
shift
target
influenza
prevent
investig
prevent
influenzalik
syndrom
herbal
prepar
appar
efficaci
herbal
prepar
prevent
influenza
like
symptom
prepar
show
better
effect
placebo
nasal
discharg
similar
result
previou
studi
use
herbal
prepar
sar
crisi
object
data
immunolog
modul
show
clear
superior
herbal
prepar
placebo
anoth
trial
healthi
volunt
aim
behavior
immunomodul
indic
ie
cell
b
cell
lymphocyt
seri
result
also
posit
seri
object
data
support
immunomodul
efficaci
herbal
prepar
threw
optim
research
use
herbal
prepar
prevent
treatment
influenza
influenzalik
upper
respiratori
viral
infect
direct
would
includ
optim
herbal
formula
vari
compon
formula
better
still
identifi
effect
fraction
gross
extract
formula
concept
diseas
prevent
herbal
medicin
one
follow
logic
immun
initi
prolong
state
posit
immunodefens
instead
mechan
action
could
much
short
term
booster
immunolog
sensit
would
benefici
earli
control
invad
viral
infect
earli
stage
season
influenza
vaccin
highli
recommend
prevent
influenza
complic
especi
high
risk
group
healthcar
worker
chronic
ill
pregnant
women
children
less
year
elderli
person
age
year
costeffect
analysi
report
pronounc
vaccin
program
could
reduc
healthcar
cost
product
loss
associ
influenza
ill
develop
countri
area
like
unit
state
unit
kingdom
canadian
australia
includ
hong
kong
implement
nation
vaccin
program
influenza
annual
form
free
subsid
offer
high
risk
group
commun
accept
prepandem
influenza
vaccin
rather
low
swine
influenza
vaccin
program
among
develop
countri
due
low
takeup
rate
abund
unus
vaccin
end
inevit
destruct
rise
popular
herbal
medicin
known
antivir
activ
immunosupport
symptom
reliev
effect
herbal
formula
could
offer
viabl
option
adjuv
vaccin
program
